Literature DB >> 18692810

Increased matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 secretion but unaffected invasiveness of endometrial stromal cells in adenomyosis.

Jehn-Hsiahn Yang1, Ming-Yih Wu, Mei-Jou Chen, Shee-Uan Chen, Yu-Shih Yang, Hong-Nerng Ho.   

Abstract

OBJECTIVE: To investigate cell invasiveness and the production of matrix metalloproteinase-2 (MMP-2), MMP-9, tissue inhibitor of metalloproteinase-1 (TIMP-1) and TIMP-2 in endometrial stromal cells (ESCs) of adenomyosis.
DESIGN: Prospective study.
SETTING: Tertiary university hospital. PATIENT(S): Twenty-one women with adenomyosis (study group) and 25 women without adenomyosis (control group). INTERVENTION(S): Endometrial stromal cells were purified from eutopic endometrium and were cultured in vitro. MAIN OUTCOME MEASURE(S): Matrigel invasion assay and measurement of MMP-2, MMP-9, TIMP-1, and TIMP-2 concentrations. RESULT(S): Endometrial stromal cell invasiveness of adenomyosis was not different from that of the control group (0.95 vs. 1, using the latter as the bench mark) in ESCs cultured alone. After the ESCs were cultured with IL-6, anti-IL-6, or GM6001 for 24 hours, the indices of cell invasion were not different between the two groups. MMP-2 (median 7.3 vs. 3.5 ng/mL) and TIMP-1 (median 12.1 vs. 3.9 ng/mL), but not MMP-9 and TIMP-2, secreted by ESCs in women with adenomyosis were much higher than those in women without adenomyosis. CONCLUSION(S): The formation of adenomyosis does not result from altered invasiveness of ESCs. The concomitant elevation of MMP-2 and TIMP-1 may partially justify why invasiveness was not increased, but other enzymes should also be considered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18692810     DOI: 10.1016/j.fertnstert.2008.05.090

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

1.  Berberine inhibits the LPS-induced proliferation and inflammatory response of stromal cells of adenomyosis tissues mediated by the LPS/TLR4 signaling pathway.

Authors:  Li Liu; Li Chen; Caixia Jiang; Jing Guo; Yan Xie; Le Kang; Zhongping Cheng
Journal:  Exp Ther Med       Date:  2017-10-16       Impact factor: 2.447

2.  Global Transcriptome Abnormalities of the Eutopic Endometrium From Women With Adenomyosis.

Authors:  Christopher N Herndon; Lusine Aghajanova; Shaina Balayan; David Erikson; Fatima Barragan; Gabriel Goldfien; Kim Chi Vo; Shannon Hawkins; Linda C Giudice
Journal:  Reprod Sci       Date:  2016-05-27       Impact factor: 3.060

3.  Differential immunohistochemical expression of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 in cow uteri with adenomyosis during follicular phase.

Authors:  Lio Moreira; Eulógio Carlos Queiroz de Carvalho; Maria Clara Caldas-Bussiere
Journal:  Vet Res Commun       Date:  2011-04-06       Impact factor: 2.459

Review 4.  Molecular Targets for Nonhormonal Treatment Based on a Multistep Process of Adenomyosis Development.

Authors:  Hiroshi Kobayashi
Journal:  Reprod Sci       Date:  2022-07-15       Impact factor: 2.924

5.  The relationship between thyroiditis and polycystic ovary syndrome: a meta-analysis.

Authors:  Danfeng Du; Xuelian Li
Journal:  Int J Clin Exp Med       Date:  2013-10-25

Review 6.  Is abnormal eutopic endometrium the cause of endometriosis? The role of eutopic endometrium in pathogenesis of endometriosis.

Authors:  Haiyuan Liu; Jing He Lang
Journal:  Med Sci Monit       Date:  2011-04

7.  Effects of diosgenin on myometrial matrix metalloproteinase-2 and -9 activity and expression in ovariectomized rats.

Authors:  Chi-Chen Chang; Tang-Ching Kuan; Yao-Yuan Hsieh; Ying-Jui Ho; Yu-Ling Sun; Chih-Sheng Lin
Journal:  Int J Biol Sci       Date:  2011-07-13       Impact factor: 6.580

Review 8.  Uterine Stem Cells and Benign Gynecological Disorders: Role in Pathobiology and Therapeutic Implications.

Authors:  Malak El Sabeh; Sadia Afrin; Bhuchitra Singh; Mariko Miyashita-Ishiwata; Mostafa Borahay
Journal:  Stem Cell Rev Rep       Date:  2020-11-05       Impact factor: 6.692

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.